Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia

Journal of Clinical Psychiatry

Volumn 62, Issue 2, 2001, Pages 92-100

  Kinon, B J ^a   Basson, B R ^a   Gilmore, J A ^a   Tollefson, G D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; OLANZAPINE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 0035108241     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n0204     Document Type: Article

References (44)

1. Efficacy of olanzapine: An overview of pivotal clinical trials
2. Safety of olanzapine
3. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
4. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone, or haloperidol
5. Prevalence of obesity in patients receiving depot antipsychotics
6. Psychotropic drugs promoting weight gain: Health risks and treatment implications
7. Weight gain associated with neuroleptic medication: A review
8. Antipsychotic-induced weight gain: A comprehensive research synthesis
9. Weight gain among schizophrenic patients treated with clozapine
10. Clozapine-induced weight gain: Prevalence and clinical relevance
11. Diabetic ketoacidosis associated with clozapine treatment
12. Clozapine and associated diabetes mellitus
13. The relationship of pharmacology to side effects
14. Are psychotropic drugs at therapeutic levels a concern for cardiologists?
15. Diabetes and schizophrenia: A preliminary study
16. Diabetes mellitus in schizophrenic patients
17. Psychotropic drugs, diabetes and chronic mental patients
18. Prevalence and correlates of diabetes in national schizophrenia samples
19. Screening for type 2 diabetes
20. Changing disease definitions: Implications for disease prevalence. Analysis of the Third National Health and Nutrition Examination Survey. 1988-1994
21. Use of ranks in one-criterion variance analysis
22. Statistical aspects of the analysis of data from retrospective studies of disease
23. The distribution of body mass index among individuals with and without schizophrenia
24. Overweight and obesity in the United States: Prevalence and trends. 1990-1994
25. Cardiovascular health risks related to overweight
26. Beitrage zum verlauf des korpergewichtes bei psychosen
27. A clinical trial of the efficacy and acceptability of D-fentluramine in the treatment of neuroleptic-induced obesity
28. Serotoninergic mechanisms in human feeding: Pharmacologic evidence
29. Increased food intake in satiated rats induced by the 5-HT antagonists methysergide, metergoline and ritanserin
30. Psychotic drug induced weight gain: Mechanism and management
31. 2C receptor
32. 2C receptor mutant mice
33. Weight gain induced by clozapine
34. Weight gain during neuroleptic treatment
35. Weight changes during treatment with phenothiazine derivatives
36. Factors influencing weight change in patients with schizophrenia treated with olanzapine versus haloperidol or risperidone
37. Severe hyperglycemia associated with high doses of clozapine
38. Nonketotic hyperglycemia associated with loxapine and amoxapine: Case report
39. Novel antipsychotics and new onset diabetes
40. Diabetic ketoacidosis associated with risperidone treatment?
41. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
42. Prolonged administration of chlorpromazine (Thorazine) hydrochloride
43. Weight change during and after hospital treatment
44. Drug-produced obesity: Experiences with chlorpromazine, perphenazine and clopenthixol